Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 3 of 3

Publication Record

Connections

Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor-associated angioedema.
Hubers SA, Kohm K, Wei S, Yu C, Nian H, Grabert R, Sexton DJ, Brown NJ
(2018) J Allergy Clin Immunol 142: 1636-1639.e5
MeSH Terms: Aged, Angioedema, Angiotensin-Converting Enzyme Inhibitors, Bradykinin, Enalapril, Female, Humans, Kininogen, High-Molecular-Weight, Lisinopril, Male, Middle Aged, Peptide Fragments, Quinapril
Added November 7, 2018
0 Communities
1 Members
0 Resources
13 MeSH Terms
Management of antiangiogenic therapy-induced hypertension.
de Jesus-Gonzalez N, Robinson E, Moslehi J, Humphreys BD
(2012) Hypertension 60: 607-15
MeSH Terms: Angiogenesis Inhibitors, Antihypertensive Agents, Carcinoma, Renal Cell, Combined Modality Therapy, Humans, Hypertension, Indoles, Kidney Neoplasms, Lisinopril, Male, Middle Aged, Nephrectomy, Pyrroles, Sunitinib, Treatment Outcome, Withholding Treatment
Added March 4, 2015
0 Communities
1 Members
0 Resources
16 MeSH Terms
Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study.
Irvin MR, Lynch AI, Kabagambe EK, Tiwari HK, Barzilay JI, Eckfeldt JH, Boerwinkle E, Davis BR, Ford CE, Arnett DK
(2010) J Hypertens 28: 2076-83
MeSH Terms: Aged, Amlodipine, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Blood Glucose, Calcium Channel Blockers, Chlorthalidone, Diabetes Mellitus, Diuretics, Double-Blind Method, Epithelial Sodium Channels, Fasting, Female, Humans, Hypertension, Lisinopril, Longitudinal Studies, Male, Middle Aged, Pharmacogenetics, Polymorphism, Single Nucleotide, Retrospective Studies, Risk Factors, Treatment Outcome
Show Abstract · Added April 23, 2015
BACKGROUND - Several clinical studies report increased risk of diabetes mellitus with pharmacologic treatment for hypertension (HTN). HTN genes may modify glycemic response to antihypertensive treatment.
METHOD - The current study examined the association of 24 single nucleotide polymorphisms (SNPs) in 11 HTN candidate genes with fasting glucose measured at 2, 4, and 6 years after treatment initiation. The study sample included participants free of diabetes at baseline in the Genetics of Hypertension Associated Treatment (GenHAT) study (N = 9309). GenHAT participants were randomized to receive treatment with a diuretic (chlorthalidone), calcium channel blocker (amlodipine), or angiotensin-converting enzyme (ACE) inhibitor (lisinopril). Mixed models for repeated measures were employed to test for gene and pharmacogenetic associations with fasting glucose during follow-up.
RESULTS - Fasting glucose at year 2 increased on average 6.8, 4.8 and 3.0 mg/dl from baseline in the chlorthalidone, amlodipine and lisinopril groups, respectively. Carrying the I allele (rs1799752) of the ACE I/D polymorphism was associated with lower fasting glucose levels (P = 0.02). Additionally, an ACE promoter polymorphism (-262, rs4291) was associated with lower fasting glucose for the model AA/AT vs. TT, which remained significant after correction for multiple testing (P = 0.001). Finally, a SNP in the α-subunit of the amiloride-sensitive epithelial sodium channel (SCNN1A, rs2228576) modified the association of amlodipine vs. chlorthalidone treatment with fasting glucose (P < 0.001).
CONCLUSION - Further examination of these genes and their relationships with cardiometabolic disease could foster development of pharmacogenetic guidelines aimed to prevent increases in fasting glucose during antihypertensive treatment.
0 Communities
1 Members
0 Resources
24 MeSH Terms